Synergy CHC Corp. SNYR
Nasdaq · XNAS · stock · Medicinal Chemicals & Botanical Products
Chart by TradingView
3/9
Piotroski F — financial health
-23.28
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $30.4M | -$12.3M | $20.3M | — | -$23.1M |
| 2024 | $34.8M | $2.1M | $23.6M | — | -$16.6M |
| 2023 | $42.8M | $6.3M | $32.1M | — | -$27.3M |
| 2019 | $29.4M | -$9.2M | $20.2M | — | -$5.2M |
| 2018 | $33.8M | -$6.2M | $22.8M | $1.2M | $4.0M |
| 2017 | $35.6M | $499,568 | $25.8M | -$984,091 | $9.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Kaushal Nitin | director | 2026-04-21 | Grant | 306,433 | — |
| Thompson Teresa Brigid | director | 2026-04-21 | Grant | 25,824 | — |
| Ross Jack | CEO and Chairman | 2025-07-30 | Buy | 100 | $3.69 |
| Ross Jack | CEO and Chairman | 2025-07-29 | Buy | 250 | $3.66 |
| Ross Jack | CEO and Chairman | 2025-07-25 | Buy | 350 | $3.90 |
| Ross Jack | CEO and Chairman | 2025-07-24 | Buy | 300 | $3.83 |
| Ross Jack | CEO and Chairman | 2025-07-22 | Buy | 300 | $3.54 |
| Ross Jack | CEO and Chairman | 2025-07-11 | Buy | 750 | $3.20 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -23.28 (distress)
- Working capital / assets 0.175
- Retained earnings / assets -5.553
- EBIT / assets -0.832
- Equity / liabilities -0.695
Source: SEC EDGAR filings · CIK 0001562733 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.